Vera Therapeutics’ fusion protein atacicept got an accelerated approval on Tuesday for a chronic autoimmune disease that damages the kidneys. The drug will be marketed as Trutakna for immunoglobulin A nephropathy …
Source: Endpoints News
You may also like
Macrophage Membrane-Derived Nanoparticles Shows...
Stem Cell Therapy Shows Promise in First Human...
Ag Genomics Begins to Bear Fruit
StockWatch: Insilico Projects Profit, Revenue Leaps as...
[Podcast] From Protocol to Patient: Inside Clinical...
KKR-backed Allyntra debuts to serve medtech industry...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.